Gazyva 1000 mg Injection 40 ml

Gazyva 1000 mg Injection 40 ml is an anti-cancer medicine used in the treatment of chronic lymphocytic leukaemia (CLL). Chronic lymphocytic leukaemia is a cancer that occurs in the bone marrow and blood. Gazyva 1000 mg Injection 40 ml is used in combination with chlorambucil for the treatment of CLL, in combination with bendamustine for the treatment of follicular lymphoma in patients who relapsed after or are refractory to a rituximab-containing regimen and in patients with previously untreated stage II bulky, III or IV follicular lymphoma.

Gazyva 1000 mg Injection 40 ml contains Obinutuzumab, which belongs to the class of monoclonal antibodies. It works by inhibiting the B-cell lymphocytes that are responsible for the multiplication of cancer cells.

Gazyva 1000 mg Injection 40 ml may cause certain side effects, such as nausea, vomiting, diarrhoea, constipation, fever, decreased platelet count, fatigue, cough, insomnia, injection site reactions and pain at the site of injection. If the side effects bother you, inform your doctor. A trained healthcare professional will administer Gazyva 1000 mg Injection 40 ml. Hence, do not self-administer.

While taking Gazyva 1000 mg Injection 40 ml if you experience any allergic reaction, inform your doctor. Before taking the Gazyva 1000 mg Injection 40 ml, let your doctor know about all your allergic or hypersensitivity reactions to medicines or food. Before receiving this injection, inform your doctor if you have any pre-existing or a history of liver/kidney disease, active infections, skin problems, or any allergic conditions. Gazyva 1000 mg Injection 40 ml is known to cause fetal B-cell depletion in neonates. Hence, inform your physician if you are pregnant.

Gazyva 1000 mg Injection 40 ml contains Obinutuzumab, which belongs to the class of CD20-directed cytolytic antibodies.  It is used in the treatment of chronic lymphocytic leukaemia and follicular lymphoma. This medicine works by binding to the CD20 antibody and causes lysis of B-cell lymphocytes responsible for the multiplication of cancer cells. This causes shrinkage of tumour cells and thereby prevents the growth and further spread of cancerous or non-cancerous cells.

Gazyva 1000 mg Injection 40 ml should be avoided if you are allergic to it or any other components present in it. Let your doctor know about your complete medical history, including current medication, to rule out any side effects/interactions. Before receiving this injection, inform your doctor if you have any history of liver/kidney disease, active infections, skin problems, or any allergic conditions. Gazyva 1000 mg Injection 40 ml may cause remission of active infections, severe skin reactions, reactivation of hepatitis B Virus, increased bilirubin levels, progressive multifocal leukoencephalopathy, tumour lysis syndrome (tumor cells release their contents into the bloodstream), and hypersensitivity reactions in some patients. Hence, careful monitoring should be done during the entire treatment. Gazyva 1000 mg Injection 40 ml may cause fetal B-cell depletion in infants. Hence, if you are pregnant or planning to become pregnant, inform your doctor beforehand. Before nursing, a breastfeeding mother should ask her oncologist whether this medicine is safe for use or not. Gazyva 1000 mg Injection 40 ml is not recommended for use in children as the safety and efficacy are not established.

• A blood test should be performed, such as a liver function test or renal function test, to check for liver/kidney function.
• Weekly blood tests should be done during the treatment to check for CBC (Complete blood count).